Alignment Healthcare, Inc. (NASDAQ:ALHC) CEO Sells $615,952.70 in Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC - Get Free Report) CEO John E. Kao sold 34,430 shares of the stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $17.89, for a total transaction of $615,952.70. Following the completion of the transaction, the chief executive officer now owns 4,923,186 shares in the company, valued at $88,075,797.54. This trade represents a 0.69 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Alignment Healthcare Trading Up 0.3 %

Shares of NASDAQ:ALHC traded up $0.07 during trading on Tuesday, hitting $18.69. The company had a trading volume of 1,833,629 shares, compared to its average volume of 1,501,379. The stock has a market cap of $3.58 billion, a price-to-earnings ratio of -24.32 and a beta of 1.49. The company has a debt-to-equity ratio of 1.82, a current ratio of 1.60 and a quick ratio of 1.60. The company has a fifty day simple moving average of $15.36 and a two-hundred day simple moving average of $13.06. Alignment Healthcare, Inc. has a one year low of $4.46 and a one year high of $18.92.

Analyst Upgrades and Downgrades

ALHC has been the topic of a number of recent research reports. Stephens reaffirmed an "overweight" rating and issued a $17.00 target price on shares of Alignment Healthcare in a report on Monday, February 24th. Barclays lifted their price objective on Alignment Healthcare from $8.00 to $9.00 and gave the company an "underweight" rating in a research report on Friday, February 28th. William Blair reissued an "outperform" rating on shares of Alignment Healthcare in a report on Friday, February 28th. Piper Sandler raised their target price on shares of Alignment Healthcare from $14.00 to $21.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 4th. Finally, Stifel Nicolaus upped their price target on shares of Alignment Healthcare from $16.00 to $18.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. One research analyst has rated the stock with a sell rating, three have given a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $14.83.

Remove Ads

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. R Squared Ltd bought a new position in Alignment Healthcare during the 4th quarter valued at about $55,000. RiverPark Advisors LLC bought a new position in shares of Alignment Healthcare during the fourth quarter valued at approximately $106,000. Tower Research Capital LLC TRC raised its holdings in shares of Alignment Healthcare by 146.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 10,571 shares of the company's stock worth $119,000 after buying an additional 6,286 shares during the period. Ballentine Partners LLC bought a new stake in shares of Alignment Healthcare during the 4th quarter worth approximately $121,000. Finally, Aigen Investment Management LP purchased a new position in Alignment Healthcare during the 4th quarter valued at $129,000. Institutional investors own 86.19% of the company's stock.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.